Liraglutide

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of various conditions

CAS	204656-20-2
Sequence	H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(N-ε-(Nα-Palmitoyl-L-γ-glutamyl))-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
Molecular Formula	C172H265N43O51
Molar Mass	3751.202 g/mol
Purity	≥98%
Storage Conditions	2-8℃
Packing Specifications	100mg、1g、10g、100g or at customers request

Additional information

Type 2 Diabetes: It is used along with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.
Weight Management: It is used as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m² or greater (obese), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).
Cardiovascular Risk Reduction: In patients with type 2 diabetes mellitus and established cardiovascular disease, it has been shown to reduce the risk of major adverse cardiovascular events such as non-fatal heart attacks, non-fatal strokes, or death from cardiovascular causes.